CA2476397A1 - Albumin-based drug delivery system and antimicrobial peptides - Google Patents
Albumin-based drug delivery system and antimicrobial peptides Download PDFInfo
- Publication number
- CA2476397A1 CA2476397A1 CA002476397A CA2476397A CA2476397A1 CA 2476397 A1 CA2476397 A1 CA 2476397A1 CA 002476397 A CA002476397 A CA 002476397A CA 2476397 A CA2476397 A CA 2476397A CA 2476397 A1 CA2476397 A1 CA 2476397A1
- Authority
- CA
- Canada
- Prior art keywords
- albumin
- fatty acid
- hsa
- peptide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000009027 Albumins Human genes 0.000 title claims abstract description 92
- 108010088751 Albumins Proteins 0.000 title claims abstract description 92
- 108700042778 Antimicrobial Peptides Proteins 0.000 title abstract description 3
- 102000044503 Antimicrobial Peptides Human genes 0.000 title abstract description 3
- 238000012377 drug delivery Methods 0.000 title description 3
- 239000000194 fatty acid Substances 0.000 claims abstract description 92
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 91
- 229930195729 fatty acid Natural products 0.000 claims abstract description 91
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 91
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 58
- 108010028921 Lipopeptides Proteins 0.000 claims abstract description 48
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 45
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 21
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 14
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 13
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 13
- 230000000975 bioactive effect Effects 0.000 claims abstract description 12
- 239000000126 substance Substances 0.000 claims abstract description 11
- 125000005313 fatty acid group Chemical group 0.000 claims abstract description 5
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 5
- 229960005486 vaccine Drugs 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 87
- 239000003814 drug Substances 0.000 claims description 18
- 235000013861 fat-free Nutrition 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 238000006073 displacement reaction Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 2
- 238000004611 spectroscopical analysis Methods 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims 2
- 108090001030 Lipoproteins Proteins 0.000 claims 2
- 102000007562 Serum Albumin Human genes 0.000 claims 2
- 108010071390 Serum Albumin Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 238000000978 circular dichroism spectroscopy Methods 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 6
- 150000002632 lipids Chemical class 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 62
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 58
- 101000755496 Canis lupus familiaris Transforming protein RhoA Proteins 0.000 description 41
- 229960003529 diazepam Drugs 0.000 description 39
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 38
- 238000001142 circular dichroism spectrum Methods 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- 108010059712 Pronase Proteins 0.000 description 32
- 235000021314 Palmitic acid Nutrition 0.000 description 29
- 238000002983 circular dichroism Methods 0.000 description 29
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 26
- 239000002953 phosphate buffered saline Substances 0.000 description 26
- 230000001580 bacterial effect Effects 0.000 description 24
- 239000012153 distilled water Substances 0.000 description 17
- 238000011534 incubation Methods 0.000 description 17
- 229940079593 drug Drugs 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- 241000588724 Escherichia coli Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000011521 glass Substances 0.000 description 14
- 239000011347 resin Substances 0.000 description 14
- 229920005989 resin Polymers 0.000 description 14
- 101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 13
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 11
- 230000007515 enzymatic degradation Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 8
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 8
- 101100337993 Arabidopsis thaliana GSO1 gene Proteins 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 7
- 229960005480 sodium caprylate Drugs 0.000 description 7
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 4
- 102100037948 GTP-binding protein Di-Ras3 Human genes 0.000 description 4
- 101100277820 Homo sapiens DIRAS3 gene Proteins 0.000 description 4
- 101100087527 Homo sapiens RHOJ gene Proteins 0.000 description 4
- 229960002446 octanoic acid Drugs 0.000 description 4
- 229940045870 sodium palmitate Drugs 0.000 description 4
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004890 malting Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940079710 sodium acetyltryptophanate Drugs 0.000 description 2
- UQSHZBSQKMVQBS-UHFFFAOYSA-M sodium;2-acetamido-3-(1h-indol-3-yl)propanoate Chemical compound [Na+].C1=CC=C2C(CC(NC(=O)C)C([O-])=O)=CNC2=C1 UQSHZBSQKMVQBS-UHFFFAOYSA-M 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- WCGVUTWEIVMUFJ-QFIPXVFZSA-N (2s)-6-amino-2-[9h-fluoren-9-ylmethoxycarbonyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N([C@@H](CCCCN)C(O)=O)C(=O)OC(C)(C)C)C3=CC=CC=C3C2=C1 WCGVUTWEIVMUFJ-QFIPXVFZSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- -1 chlorobenzyloxycarbonyl Chemical group 0.000 description 1
- 101150087654 chrnd gene Proteins 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000003664 human lactoferrin peptide 2 Human genes 0.000 description 1
- 108010057114 human lactoferrin peptide 2 Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical class C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0103877.7A GB0103877D0 (en) | 2001-02-16 | 2001-02-16 | Novel Drug Delivery system |
| GB0103877.7 | 2001-02-16 | ||
| PCT/GB2002/000680 WO2002066067A2 (en) | 2001-02-16 | 2002-02-15 | Albumin-based drug delivery system and antimicrobial peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2476397A1 true CA2476397A1 (en) | 2002-08-29 |
Family
ID=9908913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002476397A Abandoned CA2476397A1 (en) | 2001-02-16 | 2002-02-15 | Albumin-based drug delivery system and antimicrobial peptides |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20040110678A1 (enExample) |
| EP (1) | EP1359941A2 (enExample) |
| JP (1) | JP2004521911A (enExample) |
| AU (1) | AU2002229994A1 (enExample) |
| CA (1) | CA2476397A1 (enExample) |
| GB (1) | GB0103877D0 (enExample) |
| WO (1) | WO2002066067A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060258562A1 (en) * | 2000-07-31 | 2006-11-16 | Healor Ltd. | Methods and pharmaceutical compositions for healing wounds |
| WO2005013885A2 (en) | 2003-08-07 | 2005-02-17 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
| WO2007026356A2 (en) * | 2005-08-29 | 2007-03-08 | Healor Ltd. | Methods and compositions for prevention and treatment of diabetic and aged skin |
| WO2008128251A1 (en) * | 2007-04-17 | 2008-10-23 | The Children's Hospital Of Philadelphia | Humanized viral vectors and methods of use thereof |
| EP2653166A3 (en) * | 2007-07-30 | 2014-08-27 | Healor Ltd. | Pharmaceutical composition and related methods |
| ES2601827T3 (es) * | 2009-02-24 | 2017-02-16 | Arava Bio-Tech Ltd. | Agentes antagonistas de visfatina para el tratamiento del acné y de otras afecciones |
| WO2011083483A2 (en) | 2010-01-11 | 2011-07-14 | Healor Ltd. | Method for treatment of inflammatory disease and disorder |
| AT509192B1 (de) * | 2010-06-24 | 2011-07-15 | Zentrum Fuer Biomedizinische Technologie Der Donau Uni Krems | Sorptionsmittel für endotoxine |
| ES2800983T3 (es) * | 2010-12-22 | 2021-01-07 | Baxalta GmbH | Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína |
| FR3002452B1 (fr) * | 2013-02-28 | 2016-02-12 | Dermaconcept Jmc | Composition dermatologique antimicrobienne topique |
| WO2015136311A1 (en) * | 2014-03-13 | 2015-09-17 | The Secretary Of State For Health | Antimicrobial conjugates, method for production and uses thereof |
| US10071141B2 (en) * | 2015-05-08 | 2018-09-11 | Spectral Platforms, Inc. | Albumin-based non-covalent complexes and methods of use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992001476A1 (en) * | 1990-07-26 | 1992-02-06 | University Of Iowa Research Foundation | Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule |
| CA2267179A1 (en) * | 1996-09-26 | 1998-04-02 | The University Of Southern California | Methods and compositions for lipidization of hydrophilic molecules |
| WO2000033884A1 (en) * | 1998-12-04 | 2000-06-15 | Oregon Health Sciences University | Conjugates of lipids and antimicrobial or antineoplastic drugs |
| CA2375502A1 (en) * | 1999-06-23 | 2000-12-28 | The Wistar Institute Of Anatomy & Biology | Novel pyrrhocoricin-derived peptides, and methods of use thereof |
| DE10012120A1 (de) * | 2000-03-13 | 2001-09-27 | Ktb Tumorforschungs Gmbh | Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel |
-
2001
- 2001-02-16 GB GBGB0103877.7A patent/GB0103877D0/en not_active Ceased
-
2002
- 2002-02-15 US US10/468,112 patent/US20040110678A1/en not_active Abandoned
- 2002-02-15 AU AU2002229994A patent/AU2002229994A1/en not_active Abandoned
- 2002-02-15 EP EP02711103A patent/EP1359941A2/en not_active Withdrawn
- 2002-02-15 WO PCT/GB2002/000680 patent/WO2002066067A2/en not_active Ceased
- 2002-02-15 JP JP2002565625A patent/JP2004521911A/ja active Pending
- 2002-02-15 CA CA002476397A patent/CA2476397A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002229994A1 (en) | 2002-09-04 |
| JP2004521911A (ja) | 2004-07-22 |
| EP1359941A2 (en) | 2003-11-12 |
| GB0103877D0 (en) | 2001-04-04 |
| WO2002066067A3 (en) | 2003-02-13 |
| WO2002066067A2 (en) | 2002-08-29 |
| US20040110678A1 (en) | 2004-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7003183B2 (ja) | 凍結乾燥した組換え型ｖｗｆ製剤 | |
| KR101688547B1 (ko) | 아포리포단백질 ａ-ｉ 모방체 | |
| ES2590679T3 (es) | Glicopolisialilación de proteínas diferentes a proteínas de coagulación de la sangre | |
| ES2371038T3 (es) | Péptidos y derivados peptídicos así como composiciones farmacéuticas que contienen los mismos. | |
| ES2381649T3 (es) | Agentes antibacterianos que comprenden conjugados de glucopéptidos y elementos peptídicos asociados a la membrana | |
| AU2020293576B2 (en) | Pharmaceutical parenteral composition of dual GLP1/2 agonist | |
| JP2004514644A (ja) | 抗菌化合物および処方物 | |
| WO2022266060A1 (en) | Hepcidin mimetics for treatment of hereditary hemochromatosis | |
| CA2476397A1 (en) | Albumin-based drug delivery system and antimicrobial peptides | |
| Ouyang et al. | Improving the antimicrobial performance of amphiphilic cationic antimicrobial peptides using glutamic acid full-scan and positive charge compensation strategies | |
| CN116323649A (zh) | 膜联蛋白a1 n-末端肽的制剂和方法 | |
| US20080145383A1 (en) | Method for Solubilizing Peptide Mixtures | |
| CN116669752B (zh) | Glp-1/glp-2双重激动剂的药物组合物 | |
| CN116710114B (zh) | Glp-1/glp-2双重激动剂的药物组合物 | |
| ES2233924T3 (es) | Un procedimiento para preparar fragmentos terapeuticos de factor von willebrand. | |
| CA2573307C (en) | Use of platelet aggregation inhibitors | |
| WO2022129312A1 (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| AU2014237111B2 (en) | Recombinant factor VIII formulations | |
| US20240366775A1 (en) | Human transferrin receptor binding antibody-peptide conjugate | |
| CN109641938A (zh) | 衍生自精氨酸富集结构域的经修饰抗菌肽 | |
| Prada et al. | New synthetic peptides conjugated to gold nanoclusters: Antibiotic activity against Escherichia coli O157: H7 and methicillin-resistant Staphylococcus aureus (MRSA) | |
| Li et al. | Directed chemical dimerisation enhances the antibacterial activity of the antimicrobial peptide MSI-78 (4–20) | |
| RU2852511C1 (ru) | Фармацевтическая композиция двойных агонистов glp-1/glp-2 | |
| JP5673596B2 (ja) | 細胞膜透過性を有する製剤及び細胞膜透過性組成物 | |
| EP2670416B1 (en) | A novel high affinity bivalent helically constrained peptide against cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |